Simbec Research Limited ( Simbec ) and ORION Clinical Services Limited ( ORION )
|
|
- Clinton Wade
- 8 years ago
- Views:
Transcription
1 Simbec Research Limited ( Simbec ) and ORION Clinical Services Limited ( ORION ) Merger of Simbec & ORION to Create a New International Full-Service CRO Highlights: Creation of an international CRO with complete service offering from Phase I to Phase IV postauthorisation studies Appointment of a highly experienced Board, including Professor Trevor Jones CBE, Chairman, Ronald Openshaw, Chief Executive Officer and Professor Sir Christopher Evans, Non-Executive Director Completed with 12.5m of funds raised from Welsh Arthurian Life Sciences Fund and HSBC Bank plc Rationale for the merger is to create a platform for buy and build strategy and to deliver business synergies 23 June 2014: The Boards of Simbec Research Limited ( Simbec ), the specialist CRO in Early Stage Clinical Development, and ORION Clinical Services Limited ( ORION ), the specialist CRO in Late Stage Clinical Development, are pleased to announce the merger of the two companies. The Group will be known post completion as Simbec-Orion Group Limited ( Simbec-Orion or the Group ) and both the Simbec and ORION brands will continue in their respective fields. The merger has created a full service international contract research organisation (CRO) with capabilities in both Early Stage Clinical Development and Late Stage Clinical Development with deep expertise in oncology and rare and orphan diseases. The Group, with combined revenues of approximately 25m, employs approximately 250 staff and has operations across Europe, Australia and the United States together with capabilities in multiple other territories. Simbec-Orion will maintain its headquarters in the UK based in Merthyr Tydfil, South Wales. Simbec-Orion will offer its current 65 large and mid-cap pharmaceutical and biotech clients a complete service offering from first in human exploratory clinical pharmacology studies, through Phase II and Phase III studies. Currently the Group has approximately 90 clinical trials running for clients. In addition, the Group offers its clients Phase IV post authorisation studies for marketing, observational and post authorisation safety studies ( PASS ). These are complemented by in-house dedicated Central Laboratory facilities (Bioanalytics and Pathology) to rapidly, accurately and reliably read and interpret samples from all clinical trials conducted in-house as well as providing support services to its clients for additional samples and to smaller CROs without an in-house capability. In addition, Simbec-Orion can now offer a comprehensive service offering in Regulatory Affairs, Pharmacovigilance (both clinical and post marketing), Medical Affairs, and Central Pharmacy all serviced by an in-house capability. The merger was completed through the provision of 12.5m of funds raised from the Welsh Arthurian Life Sciences Fund and HSBC Bank plc s West and Wales Corporate team which provided debt finance in this leveraged transaction. Simbec was advised by Lucia Capital LLP, Geldards LLP and PriceWaterhouseCoopers LLP. ORION was advised by EY s Life Sciences Corporate Finance team and Shoosmiths LLP. Arthurian Life Sciences was advised by Eversheds. HSBC Bank plc was advised by Osborne Clarke.
2 It is the Board s and the funders intention to pursue a buy and build strategy to invest in existing operations, to drive organic growth and to rapidly pursue further acquisitions to expand its geographic reach, service offering and therapeutic areas of clinical excellence. Upon completion of the merger the Board of Directors will be joined by Ronald Openshaw as Chief Executive Officer, who joins from Lucia Capital LLP, and by Dr Fabrice Chartier as its new Chief Operating Officer, previously Director of Scientific Affairs of ORION. The Board is completed by its existing Directors Professor Trevor Jones, Non-Executive Chairman; Howard Jenkins, Managing Director; Dr Trevor Tanner, Chief Scientific Officer; and Professor Sir Christopher Evans, Non-Executive Director. At completion, Dr Alan Irvine, CEO ORION Clinical Services, has agreed to assume the role of Group Chief Medical Officer. Commenting on the merger, Professor Trevor Jones, Chairman, Simbec-Orion, said: Simbec is proud of its 30 year history of excellence in Early Stage Clinical Development. We are delighted to complete the merger with ORION which takes our Welsh headquartered company onto an international stage and expands its capability into Late Stage Clinical Development. Ronald Openshaw, Chief Executive Officer, Simbec-Orion, said: It is a privilege to join the Group as its new CEO. These two companies have traditions to be proud of. I look forward to driving the growth of the business as we invest in the Group, and to our expansion through further acquisitions. Our goal is to increase our leadership position as a trusted member of a client s team to meet their needs as they create new medicines to improve human health. Howard Jenkins, Managing Director of the Group, said: Trevor Tanner and I have directed Simbec Research over the past eleven years to create a world leader in Early Stage Clinical Development. The completion of the merger with ORION will provide continuity in our clients clinical development program and create a world class full service Clinical Research Organisation. Dr Alan Irvine, CEO, ORION Clinical Services, said: Fabrice Chartier and I founded ORION 17 years ago to create a CRO with a depth of expertise in oncology and rare and orphan diseases. We have already built a good relationship with Simbec and its team and are confident of the future for our staff and our company. The merger with Simbec expands our capabilities allowing us to meet our clients needs from the start of clinical development to registration and beyond. Professor Sir Christopher Evans, Chairman of Arthurian Life Sciences Ltd, said: My investment management team at Arthurian Life Sciences first backed Simbec in Together with HSBC we are today delighted to be leading this transaction and look forward to supporting further acquisitions for the new combined Simbec-Orion Group. Edwina Hart MBE AM, Minister for Economy, Science and Transport, said: The Welsh Government has been delighted with the growth of Simbec over the past year since Arthurian made the initial investment from our Wales Life Sciences Fund. This merger with ORION is particularly exciting and creates a Group with approximately 250 employees with a true international reach from its headquarters in Wales. We are proud to be backing such an important transaction. For more information, please contact: Consilium Strategic Communications Mary-Jane Elliott Amber Bielecka Ivar Milligan Tel: +44 (0) SimbecOrion@consilium-comms.com Simbec-Orion Group Ronald Openshaw, Chief Executive Officer Tel: +44(0)
3 Peter MacLennan, Head of Business Development Tel: +44(0) Arthurian Life Sciences Professor Sir Christopher Evans Martin Walton Brenig Preest HSBC Bank plc Craig Grant EY David Scourfield Andrew Jones Drew Wightman Tel: +44 (0) Tel: +44 (0) (0) Information about Simbec Research Limited Simbec is a specialist Early Stage Clinical development business focused on phase I healthy volunteer, first in human and first in patient studies. It was founded in 1976 and has an international reputation for excellence in this field. At the group s headquarters in Merthyr Tydfil, Wales it houses a dedicated 48 bed clinic facility to conduct those critically important first in human studies in a secure, high quality controlled environment. It is capable of undertaking studies ranging from single visit one-day trials to those lasting upwards to as much as 44 continuous days. Simbec recruits volunteers across Wales and South West of England and can complete studies rapidly due to this pool of available volunteers. Also at this location are the group s Central Laboratories equipped with state of the art facilities for the rapid testing, analysis and quantification of, biomarkers, safety and pharmacokinetic samples from clinical studies. Often providing near real time same-day results. This facility also houses the group s Central Pharmacy capable to prepare investigational medicinal product for human clinical trials. The Group will invest in these facilities to deliver greater capacity as demand increases, handling drug product for Late Stage Clinical Development. Information about ORION Clinical Services Limited ORION is a specialist CRO focused on Clinical Development in Phases I, II, and III with capabilities in Phase IV marketing, observational, and post authorization safety studies. ORION has considerable expertise in oncology, rheumatology, anaesthesia, dermatology as well as rare and orphan diseases. It has recruited experienced Project Managers and CRAs with a depth of knowledge in these indications to provide exceptionally high quality support to its clients in these fields. To support its clinical capability ORION offers its clients Regulatory Affairs & Medical Writing, Data Management and Biostatistics. ORION s Pharmacovigilance services offer clients support both in the clinical development phase and also now services clients in a seamless fashion providing post-authorisation marketing pharmacovigilance support. ORION s is based in Greater London-UK, Paris-France, Cologne-Germany, Rome-Italy, Princeton-USA and Melbourne-Australia.
4 ORION combines this therapeutic expertise and geographic reach with a highly personalised service and a keen focus on the needs of each individual project. This approach offers their pharmaceutical and biotech clients a competitive advantage to complete trials to the highest standards and in the shortest practicable timeframes. Board & Management team Professor Trevor Jones, Chairman Trevor Jones will continue in his role as Non-Executive Chairman, a position he has held in Simbec since May Professor Jones has had an outstanding career in the international pharmaceutical industry. He is a Non-Executive Director of Allergan Inc (USA), and the international CRO Synexus Ltd also a member of the Board of VeronaPharma plc. He is a visiting professor at King s College, London and holds honorary degrees and Gold Medals from 6 universities. From , he was a main board director of The Wellcome Foundation, where he was responsible for R&D including the development of AZT, Zovirax, Lamictal, Malarone and other medicines. Professor Jones is a founder member of the Geneva-based, Public / Private Partnership, Medicines for Malaria Venture (MMV) and in 2004 was appointed to the World Health Organisation (WHO) Commission on Intellectual Property Rights, Innovation and Public Health (C.I.P.I.H). For 12 years, he was a member of The UK Government regulatory agency The Medicines Commission. He was Director General of the Association of the British Pharmaceutical Industry (ABPI) a member of Council of IFPMA and the Board of EFPIA for 10 years until September He was a member of the UK Government Advisory Group on the Human Genome and, until 2008, Chair of the UK Government Advisory Group on Genetics Research. In 2005 Professor Jones won the SCRIP Life Time Achievement award for his contribution to the pharmaceutical sciences and industry, and he was honoured by Her Majesty Queen Elizabeth II by the award of CBE in the 2003 New Year's Honours List. Professor Sir Christopher Evans, Non-Executive Director Sir Chris is the founder and Chairman of Excalibur Group, and is a highly successful scientist and entrepreneur, having built over 50 medical companies and created more than $5bn of value for investors with $3bn of cash exits. He is the founder of Chiroscience, Celsis, Biovex, Merlin, Vectura and Piramed. Has also raised $2bn for cancer research projects. More recently, he has established Arthurian Life Sciences Limited to provide management services to the Wales Life Science Investment Fund, a 100 million fund and a key part of the Welsh Governments Life Sciences Initiative. Ronald Openshaw, Chief Executive Officer Ronald was appointed CEO of Simbec-Orion upon completion. He is a partner in Lucia Capital LLP a strategic advisory firm which he founded in He has previously been CEO of Plethora Solutions Holdings PLC, a urology and sexual health specialty pharmaceutical company, which he led during its successful reacquisition of its lead drug PSD502 and its approval by the European Medicines Agency. Prior to that he was also Chief Executive Officer of Pharmagene plc / Asterand plc up to 2007 leading it through that successful merger and refocusing the business. He spent a significant period of his career as a senior investment banker in the healthcare and life sciences sector with each of Jefferies and earlier Panmure Gordon & Co. After graduating in Physics he spent six years with KPMG where he qualified as a Chartered Accountant.
5 Dr Fabrice Chartier, Chief Operating Officer Fabrice was the Scientific Director of ORION. He co-founded ORION in 1997, and today is in charge of global Clinical Operations (Europe, North America, Australia). Prior to ORION, Fabrice was director and member of the board of a European CRO based in Paris before joining one of its key clients, Laboratoires Fournier. In Fournier Fabrice was Head of the Clinical Research Unit in Paris, before he was asked to set-up a Clinical Research Unit in the UK specialised in oncology and immunology, still for Fournier. Fabrice received his PhD in Biochemistry and Molecular Genetics in Paris VI University, France and he has a total of 25 years professional experience in team management and international clinical development. Dr Trevor Tanner, Chief Scientific Officer Dr Tanner completed his PhD studies in neurochemistry at The London School of Pharmacy (1976) and became a University of Wales Research Fellow in The Welsh School of Pharmacy ( ) undertaking research into the interaction of amino acid and catecholamines neurotransmitters. He was appointed Head of Bioassay Development at The Wellcome Foundation ( ). He joined Simbec Research in 1981 to establish GLP and GCP systems, progressed within Simbec Research Ltd to manage all Phase I activities and specialise in study design, pharmacokinetics, pharmacodynamics, data management and applied statistics for early stage clinical trials. He became an Executive Director and major shareholder at Simbec research in 2003, Executive Board member of Altasciences (2008) and Executive Board member of Simbec Research Ltd (2013). Howard Jenkins, Managing Director Howard Jenkins has held the post of Managing Director at Simbec since re-acquiring the company from its Canadian parent in May 2013 with backing of the Wales Life Sciences Investment Fund. Director of Finance/Company Secretary for Simbec Holdings Ltd. and Simbec Research Ltd to 2012, and Simbec Scintigraphics Ltd. from 2003 to 2006, Altasciences main board observer 2008 to Howard gained a Master of Business Administration (MBA) with overall distinction from the University of Glamorgan, also achieving distinction for his post graduate dissertation: Perceived Service Quality and Behavioural Response in the context of Clinical Research Outsourcing in the Pharmaceutical Industry. Graduate of Cardiff Business School Leadership Development Programme in 2005, member of the Institute of Directors since Dr Alan Irvine, Chief Medical Officer Alan will serve as CMO of Simbec-Orion post completion. He was co-founder, CEO and CMO of ORION. He previously spent 14 years in multinational pharmaceutical companies where he successfully held senior board level positions being responsible for medical affairs, development and regulatory affairs. He is a co-founding member of CREN (Clinical Research Expert Network), ABPI, a member of the MHRA working party on Risk Adaptive Study Design Methodology and a member of the HRA Collaboration and Development Steering Group (HRA is the Health Research Authority, a part of the DoH). To visit the Simbec Website please follow the link below:
BioWales 2015 Pharmaceutical Supply Chain Showcase. 04 March 2015
BioWales 2015 Pharmaceutical Supply Chain Showcase 04 March 2015 SIMBEC RESEARCH 40 YEARS EXPERIENCE IN EARLY STAGE CLINICAL DRUG DEVELOPMENT BACKGROUND Over 1,200 clinical studies safely and successfully
More informationThe Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry
Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge
More informationJob Profile Clinical Research Associate III (CRA)
PART 1 - PROFILE You are an experienced CRA with a strong background in Clinical Research who is passionate about drug development and are seeking a challenging and rewarding career in a quality focussed
More informationLife Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com
Life Science Sector Opportunities Northern Ireland investni.com Introduction Clinical trials commonly refer to testing the effectiveness of experimental drugs and are typically categorised into four phases;
More informationEven we will get to use your product someday. Enough reason for us to deliver.
Even we will get to use your product someday. Enough reason for us to deliver. ClinInvent: Putting our heart and soul behind the research. At ClinInvent, when we talk about clinical research it s not just
More informationCOMPANY INFORMATION DISCLOSURE
Last updated: 1 August 2014 This document is available from the company website at: www.breedonaggregates.com In conjunction with the website, this document contains all of the information which is necessary
More informationtrust When you choose an accountant, you need someone you can trust. This trust does not come from a job title - it needs to be earned.
about us trust When you choose an accountant, you need someone you can trust. This trust does not come from a job title - it needs to be earned. At Duncan & Toplis we understand this and our clients trust
More informationAnnex 7 Guidelines for the preparation of a contract research organization master file
World Health Organization WHO Technical Report Series, No. 957, 2010 Annex 7 Guidelines for the preparation of a contract research organization master file Background 1. General information 2. Quality
More informationAbt Associates Inc. Abt Associates Clinical Trials Comprehensive clinical research services
Abt Associates Inc. Abt Associates Clinical Trials Comprehensive clinical research services Providing a wide range of clinical research services Abt Associates Clinical Trials (AACT) is dedicated to providing
More informationOPKO Health to Acquire Bio-Reference Laboratories
OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition
More informationStormy weather? We ll guide you through...
Stormy weather? We ll guide you through... Because running a business isn t always plain sailing. David Rubin & Partners specialises in corporate and personal recovery, insolvency, forensic accounting
More informationEthics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient
More informationNetwork Healthcare Holdings Limited (Netcare) Netcare acquires leading private hospital group in UK
Network Healthcare Holdings Limited (Netcare) Netcare acquires leading private hospital group in UK Tuesday, 25 April 2006 Network Healthcare Holdings (Netcare), a leading international healthcare provider
More informationTHE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
More informationFirst steps to setting up your business in the UK
First steps to setting up your business in the UK 2 Crossing borders In an increasingly connected world, moving into new territories is now on the agenda for many. Greater market share, the reduced cost
More informationJoin our scientific talent community
Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into
More informationGuinness Asset Management launches Guinness EIS 4 to invest in UK Sustainable Energy companies
PRESS RELEASE Guinness Asset Management launches Guinness EIS 4 to invest in UK Sustainable Energy companies 9 October 2012 - Guinness Asset Management announces that Guinness EIS 4 is now open for investment.
More informationWhat do Birmingham postgraduates do?
1 Essential information What do Birmingham postgraduates do? School of First destinations of postgraduates Analysis of first employment destinations of postgraduates from the College of Medical and Dental
More informationHow To Design A Clinical Trial
BioBusiness BioEntrepreneurship Life Sciences Entrepreneurship BioClub BioClub BioBusiness Network at USI Clinical Trials Design and Management for Start-Up Companies LUGANO: 5-6 NOVEMBER 2012 SUPPORTED
More informationTitle of section MAKING A DIFFERENCE
Title of section MAKING A DIFFERENCE 2 Title of section ONE CULTURE ONE ETHOS ONE FIRM Our vision is to be the firm of choice for our clients and our people Our aim is to make a difference through exemplary
More informationBritish Business Bank
British Business Bank Peter Wilson CEO British Business Bank Investments ABFA Annual Conference 3 June 2015 Contents Overview of the British Business Bank Rationale Business Model Aims Programmes Impact
More informationwww.ipfin.co.uk Welcome to International Personal Finance
www.ipfin.co.uk Welcome to International Personal Finance Welcome to International Personal Finance IPF is a leading international provider of consumer finance. Our business is built around a resilient
More informationA clinical research organization
A clinical research organization About Us State of art facility. All clinical trials carried out in accordance with ICH GCP guidelines. Quality services within stipulated time period. Team of experienced
More informationPROPOSED COMBINATION OF AL NOOR HOSPITALS GROUP PLC ( AL NOOR ) AND MEDICLINIC INTERNATIONAL LIMITED ( MEDICLINIC ) AND GENERAL MEETING POLL RESULTS
Al Noor Hospitals Group Plc (Incorporated in England and Wales) Company Number 8338604 Share Code: ANH ISIN: GB00B8HX8Z88 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO ANY
More informationHealthcare. A guide to our offering
Healthcare A guide to our offering Our dedicated Healthcare Group provides an extensive range of legal services to our healthcare, pharmaceutical and medical devices clients. These clients range from start-up
More informationUnited Drug The International Healthcare Services Company
United Drug The International Healthcare Services Company UDG ID / UDG LN FORWARD LOOKING STATEMENTS Some statements in this presentation are forward looking. They represent expectations for the Group
More informationWESLEYAN INVESTMENT PORTFOLIOS UNIT TRUSTS AND ISAS
WESLEYAN INVESTMENT PORTFOLIOS UNIT TRUSTS AND ISAS 02 WESLEYAN INVESTMENT PORTFOLIOS UNIT TRUSTS AND ISAS There are thousands of investment funds available in the UK, so you may find the selection process
More informationDOLPHIN CAPITAL INVESTORS LIMITED ( DCI or Dolphin or the Company ) Directorate Changes and Review of Strategy
25 February 2015 DOLPHIN CAPITAL INVESTORS LIMITED ( DCI or Dolphin or the Company ) Directorate Changes and Review of Strategy Dolphin, a leading global investor in the residential resort sector in emerging
More informationTHE NEW WAY IN PROFESSIONAL SERVICES
THE NEW WAY IN PROFESSIONAL SERVICES THE NEW WAY IN PROFESSIONAL SERVICES VALUE At Ash St. our absolute commitment is to client satisfaction in all aspects of our work including certainty around pricing.
More informationIT Division....working in partnership
IT Division...working in partnership 96% of customers say that they would recommend Acorn to others the Acorn Group The Acorn Group is one of the leading recruitment and training specialists in the UK.
More informationAPAC CRO Market A deep dive into the trends transforming APAC CRO industry. P86A-52 June 2015
APAC CRO Market A deep dive into the trends transforming APAC CRO industry June 2015 Table of Contents Section Slide Numbers Executive Summary 10 Key Findings 11 Total CRO Market Size By Stages of Clinical
More information2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative
Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life
More informationPress release Regulated information
IBA TRADING UPDATE - THIRD QUARTER 2014 Louvain-La-Neuve, Belgium, 13 November 2014 - IBA (Ion Beam Applications S.A., EURONEXT), the world s leading provider of proton therapy solutions for the treatment
More informationManchester Pharmacy School. www.manchester.ac.uk/pharmacy
Manchester Pharmacy School Postgraduate study from Continuous Professional Development (CPD), Certificate, Diploma to Masters (MSc) with flexible, modular learning. The University of Manchester has a proud
More informationPersonalised Director Coaching Service
Personalised Director Coaching Service The IoD is offering a personalised Director Coaching Service which provides one-to-one coaching, in a confidential setting, to assist and enhance the individual performance
More informationCOMPANY INFORMATION DISCLOSURE
Last updated: 13 th July 2015 COMPANY INFORMATION DISCLOSURE This document is available from the company website at: www.pinnacletechnology.co.uk In conjunction with the website, this document contains
More informationGuinness Asset Management launches Guinness EIS 6 to invest in UK Sustainable Energy companies
PRESS RELEASE Guinness Asset Management launches Guinness EIS 6 to invest in UK Sustainable Energy companies 7 October 2014 - Guinness Asset Management announces that Guinness EIS 6 is now open for investment.
More informationRoger Dickinson, ICSA
The company secretary in the UK and their role in upholding best practice in corporate governance in banks and other organisations Roger Dickinson, ICSA The Company Secretary in the UK English law requires
More informationWWW.EZCONSULTING.COM.AU. Capability Statement
WWW.EZ.COM.AU Capability Statement Capability Statement EZ Consulting provides Business Advisory Services and Operational Support to small and medium sized businesses, specialising in: o o o o Business
More informationInsurance and compensation in the event of injury in Phase I clinical trials
Insurance and compensation in the event of injury in Phase I clinical trials Guidance developed by the Association for the British Pharmaceutical Industry, the BioIndustry Association and the Clinical
More informationCreating an international pharmacy-led healthcare group
3 October 2005 Alliance Boots plc 1 Legal disclaimer This presentation does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy any security, nor shall there be any
More informationThe Board reviews risks to the Company s business plan at its scheduled meetings.
Pharmaxis Ltd 1. Board responsibility The Pharmaxis Board is responsible for ensuring the Company establishes and maintains a risk management framework for the oversight and management of risk. The Board
More informationSpring 2013. From Our CEO. Special Event WuXi Forum - Gateway to China Chinese Premier Li Keqiang Visits WuXi Headquarter in Shanghai
From Our CEO Special Event WuXi Forum - Gateway to China Chinese Premier Li Keqiang Visits WuXi Headquarter in Shanghai Featured Story WuXi and PRA Form Joint Venture to Offer Clinical Research Services
More informationELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April 2015 13:10 14:20 Room C
ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC Thursday 16th April 2015 13:10 14:20 Room C 1 Contents Programme.... 2 Welcome message.... 3 Faculty biographies.... 4 Symposium
More informationThe Association of Investment Companies. Going for growth. A guide to Venture Capital Trusts
The Association of Investment Companies Going for growth February 2015 www.theaic.co.uk Venture Capital Trusts provide finance to some of the most dynamic small businesses in the UK to help them grow.
More informationMoney Without Frontiers
Money Without Frontiers Universal Foreign Exchange Sterling House Fulbourne Road London E17 4EE United Kingdom Dealing Desk Tel: +44 (0)20 8498 2777 Dealing Desk Fax: +44 (0)20 8527 2848 Switch Board Tel:
More informationAn investment in knowledge pays the best interest. - Benjamin Franklin
An investment in knowledge pays the best interest. - Benjamin Franklin Investing in Future Business Leaders Prodigy Finance bonds fund talented international students, to attend the world s top business
More informationCLINICAL RESEARCH NETWORK
CLINICAL RESEARCH NETWORK Introduction The vision of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. This document sets out how the
More informationDR MARGARET CULLEN (PROGRAMME DIRECTOR) Subject Area: Bank Governance
DR MARGARET CULLEN (PROGRAMME DIRECTOR) Subject Area: Bank Governance Dr. Margaret Cullen is a specialist in the areas of corporate and investment fund governance. Margaret holds a BA in Economics from
More informationCHARTERED BANKER MBA TM
BANGOR BUSINESS SCHOOL, EXECUTIVE EDUCATION CHARTERED BANKER MBA TM The MBA from an internationally renowned Business School for Banking* in partnership with the world s oldest professional Institute of
More informationDirectors and Senior Management
Directors and Senior Management Victor FUNG Kwok King Group Non-Executive Chairman Chairman of Nomination Committee and Risk Management Committee Victor FUNG Kwok King, aged 58, brother of Dr William FUNG
More informationgellerbiopharm A healthcare investment banking division of Financial West Group, member FINRA/SIPC. Office (212) 315-0600 Web gellerbp.
gellerbiopharm A healthcare investment banking division of Financial West Group, member FINRA/SIPC. Office (212) 315-0600 Web gellerbp.com Summary Personal Financing LM&A Network Diverse, world-class team
More informationSteven E. Wolf, MD, FACS, University of Texas Southwestern
Steven E. Wolf, MD, FACS, University of Texas Southwestern Dr. Wolf is an established researcher and clinician in the field of burn/trauma care. He is currently the Chief of Burn Services and Vice Chairman
More informationIndustry NHS data sharing for collaborative product development
Industry NHS data sharing for collaborative product development Changing strategies in clinical evidence gathering: Are randomised, doubleblinded studies to become extinct? The RCT is not extinct, but
More informationInternational Advisory Panel to Advise on Issues on Problem Gambling and Addictions
International Advisory Panel to Advise on Issues on Problem Gambling and Addictions The Ministry of Health (MOH), and the Ministry of Community Development, Youth and Sports (MCYS) have set up an International
More informationFact Sheet August 2014
Fact Sheet August 2014 Read Now Print Now bank Paragon Bank is part of the FTSE 250 Paragon Group of Companies, the UK s leading independent, buy-to-let lender and consumer finance specialist... bank car
More informationChemicals and Life Sciences Industry Practice. Insurance and compensation in the event of injury in Phase I clinical trials in the United Kingdom
Chemicals and Life Sciences Industry Practice Insurance and compensation in the event of injury in Phase I clinical trials in the United Kingdom i Insurance and compensation in the event of injury in Phase
More informationSymposium on Health Informatics
Symposium on Health Informatics Hosted by the Faculty of Pharmaceutical Sciences and Faculty of Medicine Tuesday, April 5, 2016 8:30 a.m. 5:30 p.m. Life Sciences Institute, LSC3 2350 Health Sciences Mall,
More informationThe Association for Clinical Biochemistry & Laboratory Medicine Strategic Plan
The Association for Clinical Biochemistry & Laboratory Medicine Strategic Plan Background The ACB has been in existence for 60 years. During that time, laboratory medicine has changed in a way that must
More informationFuture Specialisation for Pharmacists in Industry
Future Specialisation for Pharmacists in Industry JANE NICHOLSON Executive Director European Industrial Pharmacists Group (EIPG) Innovation gap... Cost is now ~ 700-1billion Success Rate 1 in 10,000 By
More informationGeneral Legal Service Provider Information Form
General Legal Service Provider Information Form General information Name of Organisation LK Shields Solicitors Contact information Head of Organisation: Hugh Garvey (Managing Partner) Name: LK Shields
More informationHarwood Wealth Group plc ( Harwood Wealth, the Company or the Group ) Announcement of intention to float on AIM
11 March 2016 Harwood Wealth Group plc ( Harwood Wealth, the Company or the Group ) Announcement of intention to float on AIM Harwood Wealth (AIM: HW.), a leading UK-based vertically integrated financial
More informationInternational Business Symposium
International Business Symposium Treaty-based Solutions for International Business Wednesday, October 9, 2013 7:00 a.m. to 11:30 a.m. The Westin Edmonton Edmonton, AB PROGRAMME Co-ordinator: Mr. Kenneth
More informationProfessional Indemnity Division. An Introduction
01 Professional Indemnity Division An Introduction 02 Professional Indemnity Division The Howden way We believe in building relationships based on trust and respect. We work with businesses that take their
More informationCompany Overview. Contact: info@ostiasolutions.com. Address: 6 The Mill Building, The Maltings, Bray, Co Wicklow. Web: www.ostiasolutions.
Company Overview Contact: info@ostiasolutions.com Address: 6 The Mill Building, The Maltings, Bray, Co Wicklow Web: www.ostiasolutions.com Phone: +353 1 276 80 48 About Ostia Solutions Ostia Solutions
More informationGOVERNANCE SYMPOSIUM 2016. Friday, 22nd April 2016
GOVERNANCE SYMPOSIUM 2016 Friday, 22nd April 2016 GOVERNANCE SYMPOSIUM 2016 John Ralston Chairman, AISNSW Board Friday, 22 nd April 2016 Sydney Cricket Ground, Driver Ave, Moore Park, Sydney The introduction
More informationAlberta Health Services Board of Directors
Alberta Health Services Board of Directors The biographies of the newly appointed Alberta Health Services Board of Directors are linked in the list below: Linda Hughes, Chair... 2 Dr. Brenda Hemmelgarn,
More information19 October 2006. Company Announcement Office Bendigo Stock Exchange PO Box 191 Flinders Lane, Melbourne Vic 8009. By email; announcements@bsx.com.
19 October 2006 Company Announcement Office Bendigo Stock Exchange PO Box 191 Flinders Lane, Melbourne Vic 8009 By email; announcements@bsx.com.au RE: Announcement by State Development Fund Limited Please
More informationVENTURE CAPITAL LOAN FUND FINANCED FROM ERDF
VENTURE CAPITAL LOAN FUND FINANCED FROM ERDF The case of Northwest England: Challenges, Achievements and Perspectives David Malpass, Director of ERDF European Programme, Northwest England OVERVIEW Background
More informationThe Group s strength is derived from the intelligent combination and leverage of both the Phoenix Life and Ignis Asset Management businesses.
Last updated 1 February 2013 MEDIA FACTSHEET PHOENIX GROUP Phoenix Group is the UK s largest specialist closed life and pension fund consolidator with over 6 million policyholders and 71.6 billion* of
More informationTHE LINCOLN INSTITUTE OF HEALTH
THE LINCOLN INSTITUTE OF HEALTH Background The Chair in the Care of the Older Person will be part of the new Lincoln Institute of Health, a cross disciplinary research collaboration linking schools, colleges
More informationRevenues before Reimbursements. Add back: Depreciation and Amortization Expense. Diluted Earnings Per Share. Selected Other Information
2003 Annual Report Navigant Consulting Navigant Consulting is a specialized independent consulting firm that assists clients in addressing the critical challenges of dispute and litigation, regulation,
More informationHealthcare. Healthcare FOR HEALTHCARE PROFESSIONALS. Businesses & ORGANISATIONS. www.sintons.co.uk
Healthcare Healthcare FOR HEALTHCARE PROFESSIONALS Businesses & ORGANISATIONS www.sintons.co.uk HEALTHCARE IS IN OUR BLOOD... Combining specialist lawyers from across the firm, our expert healthcare team
More information( Leni Gas Cuba Limited ) Application for Admission to ISDX Growth Market Proposed Subscription
16 October 2015 LENI GAS CUBA LIMITED ( Leni Gas Cuba Limited ) Application for Admission to ISDX Growth Market Proposed Subscription The Directors of Leni Gas Cuba Limited ( Leni Cuba or the Company )
More informationRoddy Sage, Executive Chairman Equiom Hong Kong
Roddy Sage, Executive Chairman Roddy is an associate member of the Institute of Taxation, with over thirty years experience in accounting, international tax planning and investment structuring, enhanced
More informationInterview with Professor Peter Dobson, Academic Director of the Oxford University Begbroke Business and Science Park
Analytic Department IAA Investika, Ltd. Tel.: +7 (495) 626 49 57 Contact person: Natalya Zhuravleva n.zhuravleva@investika.ru http://www.investika.ru Interview with Professor Peter Dobson, Academic Director
More informationSalary Survey 2014. Domestic, International Salary Survey and Country Cost Analysis
Salary Survey 2014 Domestic, International Salary Survey and Country Cost Analysis Disclaimer: This salary guides contained herewith have been constructed to represent average salaries across a range of
More informationFocus on Corruption: Seven Views to Consider
Focus on Corruption: Seven Views to Consider Panel Chair Peter Morris CA PPB Advisory Peter is a Chartered accountant and a of the PPB Forensic practice. He has over 27 years experience in investigation
More informationClark Group Overview 2 Private Equity 4 Mergers & Acquisitions 6 Industry Specialism 8 Typical Engagement 10 Our Strengths 12
connected ventures content data commerce Clark Group Overview 2 Private Equity 4 Mergers & Acquisitions 6 Industry Specialism 8 Typical Engagement 10 Our Strengths 12 greencape Team 14 Contact Details
More informationPublic Disclosure Information
Annex B Public Disclosure Information For the financial year ended 31 December 2014 Document Date: 9 April 2015 1. Corporate Profile Raffles Health Insurance Pte. Ltd. ( RHI or the Company ) was incorporated
More informationVenture Capital in Australia
Venture Capital in Australia Venture Capital in Australia Australia offers attractive investment opportunities and significant early-stage investment support. Innovation is a key driver of economic performance.
More informationMaster of Science in Biomedical Sciences
Master of Science in Biomedical Sciences Faculty of Medicine Good health is our greatest treasure. Understanding the human body, healthy and diseased, is the stepping stone to finding tools to improving
More informationLife Sciences & Healthcare
Life Sciences & Healthcare 03 Taylor Wessing is a leading European law firm advising life sciences and healthcare businesses, those who fund them and those who work for them Taylor Wessing has been voted:
More informationBirmingham and Solihull LETC - Council Members
Birmingham and Solihull LETC - Council Members Council Members Tracy Taylor- Chair is chief executive of Birmingham Community Healthcare NHS Trust, which provides more than 130 community and specialist
More informationPepper Group Announces Acquisition of Oakwood Loan Servicing & Asset Management Platform
Press Release Wednesday, 11 September 2013 London, England Pepper Group Announces Acquisition of Oakwood Loan Servicing & Asset Management Platform Australian specialist financial services group, Pepper
More informationAvacta Group plc! Innovation for global health! Interim Results! 25th April 2012!
Avacta Group plc Innovation for global health Interim Results 25th April 2012 Important Notice This presentation does not constitute a recommendation regarding the shares of Avacta Group plc (the Company
More informationKnowledge. Experience. Independence.
Knowledge. Experience. Independence. ABOUT US Global Funds Management Ltd (GFM) is a boutique corporate management firm in the Cayman Islands serving the alternative investment management industry. GFM
More informationImproving the Quality & Efficiency of the NHS Estate Innovative Solutions for a Transformed NHS Estate FREE HALF-DAY CONFERENCE
Improving the Quality & Efficiency of the NHS Estate Innovative Solutions for a Transformed NHS Estate Itinerary 09.15 09.30 09.45 10.15 11.10 11.30 12.00 12.30 12.45 Registration and coffee Welcome by
More informationIONIQ Capital Partners Limited
CORPORATE PROFILE A message from our Chairman: The current market conditions make choosing a reliable partner more important than ever, so if you are a buyer or seller of commodities looking to close more
More informationAnalyst & Investor Presentation Interim results to 30 June 2011
Analyst & Investor Presentation Interim results to 30 June 2011 Ian Temple - Executive Chairman Tim Smeaton - Chief Executive Officer John Glover - Finance Director www.hydrogengroup.com Summary Introduction
More informationexactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
More information2.2 Reviewing the company s internal financial controls and the company s internal control and risk management systems;
Beazley plc Audit and Terms of reference Approved by board resolution dated 23 July 2015 1. Objectives To assist the board of directors in fulfilling its oversight responsibilities for the financial reporting
More informationRevision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices. Response from Cancer Research UK to the Commission August 2010
Revision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices Response from Cancer Research UK to the Commission August 2010 1. Cancer Research UK (CR-UK) 1 is leading the world in finding
More informationWestpac Group today announced the launch of the Bank of Melbourne in August 2011. Please refer to the attached media release.
Westpac Banking Corporation ABN 33 007 457 141 Group Secretariat Level 20, 275 Kent Street Sydney NSW 2000 Australia Phone +61 (0)2 8219 8990 Facsimile + 61 (0)2 8253 1215 10 March 2011 Company Announcements
More informationQUBIS Ltd and The Chief Executives Club at Queen s
QUBIS Ltd and The Chief Executives Club at Queen s Why settle for Bronze when the Gold is out there? Exploring funding options essential for your company s growth A morning of presentations and discussion
More informationLearning Event for Health Care Assistants & Assistant Practitioners
Learning Event for Health Care Assistants & Assistant Practitioners 28 April 2014 AFC Bournemouth Dean Court Kings Park Bournemouth BH7 7AF It takes a remarkable person to be a nurse. This is challenging.
More informationThe ReThink Group plc ( ReThink Group or the Group ) Unaudited Interim Results. Profits double as strategy delivers continued improved performance
The ReThink Group plc ( ReThink Group or the Group ) Unaudited Interim Results Profits double as strategy delivers continued improved performance The Group (AIM: RTG), one of the UK s leading recruitment
More informationIFA Solutions. Flexible retirement and business options
IFA Solutions Flexible retirement and business options Who are AFH? AFH is a leading financial planning led wealth management firm. With headquarters in Bromsgrove, we advise clients across the UK and
More information